Trichotillomania is characterized by repetitive pulling that causes noticeable hair loss. Data on the pharmacological treatment of trichotillomania are limited, with no clear first-line agent. The aim of the current study was to determine the efficacy and tolerability of inositol in adults with trichotillomania. A total of 38 individuals (35 women; mean age: 28.9±11.4) with trichotillomania entered a 10-week, double-blind, placebo-controlled trial to evaluate the safety and efficacy of inositol (dosing ranging from 6 to 18 g/day). Patients were assessed using the Massachusetts General Hospital Hair Pulling Scale, the NIMH Trichotillomania Severity Scale, Clinical Global Impression Scale, and measures of depression, anxiety, and psychosocial functioning. Outcomes were examined using a linear mixed-effects model. Patients assigned to inositol failed to show significantly greater reductions on primary or secondary outcomes measures compared with placebo (all P>0.05). At study endpoint, 42.1% of patients were 'much or very much improved' on inositol compared with 35.3% on placebo. This is the first study assessing the efficacy of inositol in the treatment of trichotillomania, but found no differences in symptom reductions between inositol and placebo. Future studies should examine whether inositol may be beneficial in controlling pulling behavior in a subgroup of individuals with trichotillomania.

中文翻译：

---

毛滴虫病中肌醇的双盲，安慰剂对照研究。

毛滴虫的特征是反复拉动，引起明显的脱发。关于毛滴虫病的药理治疗数据有限，尚无明确的一线药物。本研究的目的是确定肌醇在毛滴虫病成人中的疗效和耐受性。共有38个人（35名女性；平均年龄：28.9±11.4）患有毛滴虫病，进行了为期10周，双盲，安慰剂对照的试验，以评估肌醇的安全性和有效性（剂量为6至18 g /天） ）。使用马萨诸塞州综合医院的头发拉动量表，NIMH Trichotillomania严重程度量表，临床总体印象量表以及抑郁，焦虑和心理社会功能的量度对患者进行评估。使用线性混合效应模型检查结果。与安慰剂相比，分配给肌醇的患者在主要或次要结局指标上没有显示出更大的降低（所有P> 0.05）。在研究终点，肌醇中42.1％的患者“或多或少有改善”，而安慰剂组为35.3％。这是评估肌醇治疗毛滴虫病功效的第一项研究，但发现肌醇和安慰剂之间在症状减轻方面无差异。未来的研究应该检查肌醇是否在控制毛滴虫病的一个亚组中对控制拉举行为是否有益。这是评估肌醇治疗毛滴虫病功效的第一项研究，但发现肌醇和安慰剂之间在症状减轻方面无差异。未来的研究应该检查肌醇是否在控制毛滴虫病的一个亚组中对控制拉举行为是否有益。这是评估肌醇治疗毛滴虫病功效的第一项研究，但发现肌醇和安慰剂之间在症状减轻方面无差异。未来的研究应该检查肌醇是否在控制毛滴虫病的一个亚组中对拉动行为的控制是否有益。